Issued on behalf of GT Biopharma, Inc. [1][2] VANCOUVER, BC, Dec. 19, 2025 /PRNewswire/ -- USA News Group News Commentary – The recent FDA approval in November of the first bispecific antibody combination for second-line blood cancer treatment marks the departure from traditional chemotherapy that oncologists have been anticipating for decades. Engineered cell therapies and bispecific antibodies are now achieving response rates exceeding 90% in patients with relapsed and refractory hematologic malignancies, ...